By vgreene, 12 March, 2021 Consider DOACs over vit K antagonists VKA in most pts 2 no DOAC preferred over another 3 if unable to use DOACs VKA initial heparin tx preferred over LMWH alone4
By vgreene, 12 March, 2021 Consider home tx or early d c for pts w uncomplicated DVT or PE at low risk for complications1
By vgreene, 12 March, 2021 Additional considerations for pts w known CA 5 per ASCO IVC filter should be last resort no survival benefit and uarr long term risk for VTE development ASH also suggests not using IVC filter in pts w CA recurrent VTE on anticoagulation
By vgreene, 12 March, 2021 Recurrent VTE while on therapeutic anticoagulant tx is unusual should prompt 1 re eval of whether there truly was recurrent VTE 2 eval of compliance w anticoagulant tx 3 consideration of underlying CA
By vgreene, 12 March, 2021 For pts w breakthrough DVT PE on long term LMWH Consider uarr dose4 by 1 4 to 1 3 per ACCP
By vgreene, 12 March, 2021 For pts w breakthrough DVT PE during therapeutic VKA or DOAC tx Consider switching to LMWH for at least 1mo per ACCP if INR control poor on VKA switch to DOAC may be reasonable3
By vgreene, 12 March, 2021 Consider home tx or early d c for pts w uncomplicated DVT or PE at low risk for complications1 2
By vgreene, 12 March, 2021 Recurrence usually warrants indefinite antithrombotic tx Breakthrough VTE PE on vit K antagonist VKA or DOAC is unusual warrants additional eval
